<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00187681</url>
  </required_header>
  <id_info>
    <org_study_id>865</org_study_id>
    <nct_id>NCT00187681</nct_id>
  </id_info>
  <brief_title>Organic Cation Transporter 1 (OCT1), on Response to Metformin in Healthy Subjects</brief_title>
  <official_title>Effect of Genetic Variants in the Xenobiotic Transporter, OCT1, on Response to Metformin in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Specific Objectives:

        -  To determine if individuals who carry a decreased or non-functional variant of OCT1
           exhibit differences in the pharmacokinetics of metformin in comparison to individuals
           who carry the common allele.

        -  To determine if individuals who carry the decreased or non-functional variants exhibit
           differences in the response to metformin in comparison to individuals who carry the
           common allele.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the proposed studies, we will address two questions:

      •Do individuals who carry one of OCT1 variants with reduced or no function exhibit
      differences in the pharmacokinetics of metformin in comparison to individuals who carry the
      common allele?

      Compared to wild type mice, Oct1-/- mice have reduced metformin distribution to the liver and
      intestine. We expect a similar pattern between persons who carry the variant OCT1 allele and
      those who carry the common allele. This effect might be reflected by a difference of Tmax or
      Cmax after oral administration of metformin. Other differences in metformin pharmacokinetic
      properties such as volume of distribution, half life and clearance may also be evident.

      •Do individuals who carry the decreased or non-functional variants exhibit differences in the
      response to metformin in comparison to individuals who carry the common allele? Specially, we
      will test the hypothesis that the OCT1-expressing tissues are target organs for metformin,
      and that individuals with the variant transporters may have reduced metformin uptake into
      these sites (is this the correct meaning?) and therefore a reduced drug response to
      metformin.

      In this study, we will evaluate metformin pharmacokinetics and glucose metabolic effects in
      healthy subjects rather than in patients with type 2 diabetes. Our rationale is as follows.
      The hepatic glucose production in diabetic patients is abnormally increased. Metformin
      decreases fasting blood glucose concentration by reducing hepatic glucose production and
      improving glucose utilization. However, the fasting blood glucose concentration is not
      decreased by metformin in non-diabetics who have a normal hepatic glucose production. It was
      suggested that the glucose-lowering effect of metformin was difficult to demonstrate in
      non-diabetics unless glucose concentrations were artificially raised. Although there are
      studies showing that metformin improves the glucose tolerance both in non-diabetics and
      diabetics, the results for non-diabetics have been inconsistent, depending on the variable
      experimental condition. Variation in OCT1 expression and activity may be one of those
      variables, and the time points for blood sampling after drug and glucose (meal) intakes may
      also be important to observe the glucose-lowering effect [16]. In this study, we employ a
      similar study design as that reported [16] to observe the glucose-lowering effect by
      metformin in healthy subjects. Before and after metformin administration, oral glucose
      tolerance test (OGTT) will be conducted. We expect a difference of glucose tolerance between
      different OCT1 genotypes, under the hypothesis that individuals with different OCT1 genotypes
      have different metformin concentrations in the target tissues, and hence have different
      glucose uptakes into (and so utilization in) the target tissues (primary muscle and liver).

      In non-diabetic healthy subjects, metformin significantly attenuated the rise in immediate
      postprandial insulin levels. In this study, we will also determine insulin levels after
      glucose administration. With metformin treatment, we expect to observe significant difference
      in post-glucose-administration insulin levels between individuals with different OCT1
      genotypes.

      When mice were given metformin, the blood lactate concentration significantly increased in
      the wild-type mice, whereas only a slight increase was observed in Oct1-/- mice. This is
      consistent with our hypothesis that OCT1 is a determinant of metformin effect on glucose
      utilization. It will be interesting to compare plasma lactate concentrations after metformin
      treatment between individuals with different OCT1 genotypes.

      Metformin can improve lipid metabolism in obese and diabetics patients, which is reflected by
      the reduced plasma levels of free fatty acid, cholesterol, and triglycerides. However, in
      this study with a single dose of metformin, it may not be possible to observe those effects
      in healthy subjects, although the corresponding concentrations will be measured.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) of Blood Concentration-time of Metformin</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, and 24 hours</time_frame>
    <description>To test whether individuals with genetic variants of human organic cation transporter, OCT1, exhibit altered pharmacokinetics of metformin, the difference in AUC of blood concentration-time of metformin between reference and variant groups will be measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucose Lowering Response to Metformin</measure>
    <time_frame>0 to 180 minutes</time_frame>
    <description>To test whether individuals with genetic variants of human organic cation transporter, OCT1, exhibit altered glucose lowering response to metformin we will measure the difference in area under the glucose concentrations-time curve (Glucose AUC) following oral glucose tolerance test.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Other Conditions That May Be A Focus of Clinical Attention</condition>
  <arm_group>
    <arm_group_label>OCT1-variant Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with OCT1-variant alleles will be dosed with 2 doses of Metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OCT1-reference Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with OCT1-reference alleles will be dosed with 2 doses of Metformin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>2 doses of Metformin Day 1 1000mg, Day 2 850 mg</description>
    <arm_group_label>OCT1-variant Group</arm_group_label>
    <arm_group_label>OCT1-reference Group</arm_group_label>
    <other_name>Dimethylguanylguanidine</other_name>
    <other_name>Glucophage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previous participation in the Study Of Pharmacogenetics In Ethnically Diverse
             Populations (SOPHIE) study.

          -  Between the ages of 18 and 40.

          -  Possess a specific OCT1 genotype.

        Exclusion Criteria:

          -  Taking any medications other than vitamins

          -  Individuals with anemia (hemoglobin &lt; 12 g/dL), an elevation in liver enzymes to
             higher than double the respective normal value, or elevated creatinine concentrations
             (males ≥ 1.5 mg/dL, females ≥ 1.4 mg/dL)

          -  Pregnant at time of study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen M Giacomini, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco General Hospital</name>
      <address>
        <city>San Francsico</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, Burchard EG, Brett CM, Giacomini KM. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 2007 May;117(5):1422-31.</citation>
    <PMID>17476361</PMID>
  </results_reference>
  <results_reference>
    <citation>Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP, Sheardown SA, Yue L, Burchard EG, Brett CM, Giacomini KM. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther. 2008 Feb;83(2):273-80. Epub 2007 Jul 4.</citation>
    <PMID>17609683</PMID>
  </results_reference>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <results_first_submitted>May 20, 2011</results_first_submitted>
  <results_first_submitted_qc>December 6, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 8, 2013</results_first_posted>
  <last_update_submitted>December 6, 2012</last_update_submitted>
  <last_update_submitted_qc>December 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy controls</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Organic Cation Transporter 1 (OCT1)-Variant Group</title>
          <description>Subjects with OCT1-variant alleles to be dosed with 2 doses of Metformin (total 1850 mg).</description>
        </group>
        <group group_id="P2">
          <title>Organic Cation Transporter 1 (OCT1)-Reference Group</title>
          <description>Subjects with OCT1-reference alleles to be dosed with 2 doses of Metformin (total 1850 mg).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>OCT1-variant Group</title>
          <description>Subjects with OCT1-reference alleles to be doses with 2 doses of Metformin (total 1850 mg).</description>
        </group>
        <group group_id="B2">
          <title>OCT1-reference Group</title>
          <description>Subjects with OCT1-reference alleles to be doses with 2 doses of Metformin (total 1850 mg).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.0" spread="5.9"/>
                    <measurement group_id="B2" value="31.3" spread="5.4"/>
                    <measurement group_id="B3" value="30.5" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve (AUC) of Blood Concentration-time of Metformin</title>
        <description>To test whether individuals with genetic variants of human organic cation transporter, OCT1, exhibit altered pharmacokinetics of metformin, the difference in AUC of blood concentration-time of metformin between reference and variant groups will be measured.</description>
        <time_frame>0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, and 24 hours</time_frame>
        <population>20 participants were analyzed as per protocol. The sample size of 20 subjects enabled us to detect a significant difference (at the p &lt; 0.05 level; α = 0.05, β = 0.80) in the pharmacokinetics of metformin between individuals who are homozygous for the reference OCT1 and those who carry an OCT1-R61C, OCT1-G401S or OCT1-G465R allele.</population>
        <group_list>
          <group group_id="O1">
            <title>OCT1-variant Group</title>
            <description>Metformin blood concentration-time profiles in subjects carrying the variant OCT1 genotypes (ie. carries at least one of the four variant alleles OCT1-R61C, G401S, 420del, and/or OCT1-G465R).</description>
          </group>
          <group group_id="O2">
            <title>OCT1-reference Group</title>
            <description>Metformin blood concentration-time profiles in subjects carrying the reference OCT1 allele at all the four positions in the OCT1 gene.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) of Blood Concentration-time of Metformin</title>
          <description>To test whether individuals with genetic variants of human organic cation transporter, OCT1, exhibit altered pharmacokinetics of metformin, the difference in AUC of blood concentration-time of metformin between reference and variant groups will be measured.</description>
          <population>20 participants were analyzed as per protocol. The sample size of 20 subjects enabled us to detect a significant difference (at the p &lt; 0.05 level; α = 0.05, β = 0.80) in the pharmacokinetics of metformin between individuals who are homozygous for the reference OCT1 and those who carry an OCT1-R61C, OCT1-G401S or OCT1-G465R allele.</population>
          <units>hour * µg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9,200" spread="1,200"/>
                    <measurement group_id="O2" value="7,700" spread="970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Glucose Lowering Response to Metformin</title>
        <description>To test whether individuals with genetic variants of human organic cation transporter, OCT1, exhibit altered glucose lowering response to metformin we will measure the difference in area under the glucose concentrations-time curve (Glucose AUC) following oral glucose tolerance test.</description>
        <time_frame>0 to 180 minutes</time_frame>
        <population>20 participants were analyzed as per protocol. The sample size of 20 subjects enabled us to detect a significant difference (at the p &lt; 0.05 level; α = 0.05, β = 0.80) in the pharmacodynamics of metformin between individuals who are homozygous for the reference OCT1 and those who carry an OCT1-R61C, OCT1-G401S or OCT1-G465R allele.</population>
        <group_list>
          <group group_id="O1">
            <title>OCT1-variant Group</title>
            <description>Glucose lowering response to metformin (Glucose AUC) in subjects carrying variant OCT1 genotypes (ie. carries at least one of four variant alleles OCT1-R61C, G401S, 420del, and/or OCT1-G465R).</description>
          </group>
          <group group_id="O2">
            <title>OCT1-reference Group</title>
            <description>Glucose lowering response to metformin (Glucose AUC) in subjects carrying the reference OCT1 genotype at all the four positions in the OCT1 gene.</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Lowering Response to Metformin</title>
          <description>To test whether individuals with genetic variants of human organic cation transporter, OCT1, exhibit altered glucose lowering response to metformin we will measure the difference in area under the glucose concentrations-time curve (Glucose AUC) following oral glucose tolerance test.</description>
          <population>20 participants were analyzed as per protocol. The sample size of 20 subjects enabled us to detect a significant difference (at the p &lt; 0.05 level; α = 0.05, β = 0.80) in the pharmacodynamics of metformin between individuals who are homozygous for the reference OCT1 and those who carry an OCT1-R61C, OCT1-G401S or OCT1-G465R allele.</population>
          <units>min * mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18,200" spread="1,600"/>
                    <measurement group_id="O2" value="21,300" spread="2,290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>OCT1-variant Group</title>
          <description>Subjects with OCT1-reference alleles to be doses with 2 doses of Metformin (total 1850 mg).</description>
        </group>
        <group group_id="E2">
          <title>OCT1-reference Group</title>
          <description>Subjects with OCT1-reference alleles to be doses with 2 doses of Metformin (total 1850 mg).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kathy Giacomini, Ph.D</name_or_title>
      <organization>UCSF</organization>
      <phone>4154761936</phone>
      <email>Kathy.Giacomini@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

